Does BCBSTX Cover Wegovy for Weight Loss? The 2026 Policy Reality and Your Four Workarounds

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• BCBSTX (Blue Cross Blue Shield of Texas) covers Wegovy only for employer groups that specifically purchase the obesity medication rider, which represents approximately 18% of commercial BCBSTX plans as of 2026
• Most individual marketplace plans, Medicare Advantage plans administered by BCBSTX, and standard employer plans exclude all obesity medications including Wegovy under the "weight management exclusion" clause
• Prior authorization requires BMI 30+ (or 27+ with comorbidity), documented 6-month physician-supervised weight loss attempt, and specific diagnostic codes, with average approval time of 14 to 21 business days
• Four viable alternatives exist: compounded semaglutide at $297/month, manufacturer savings programs for commercially insured patients, clinical trial enrollment, and plan-year switching during open enrollment

Direct answer (40-60 words)

BCBSTX covers Wegovy for weight loss only if your specific plan includes the optional obesity medication rider. Most BCBSTX plans exclude weight-loss medications by default. Coverage requires prior authorization, BMI criteria, documented weight loss attempts, and specific comorbidities. Approximately 82% of BCBSTX members do not have obesity medication coverage as of 2026.

Table of contents

1. The baseline answer: which BCBSTX plans cover Wegovy
2. How to check your specific plan in under 3 minutes
3. The prior authorization process: requirements and timeline
4. Why most employer groups exclude the obesity rider
5. What most coverage articles get wrong about "medical necessity"
6. The four-path decision tree when BCBSTX says no
7. Compounded semaglutide: the clinical equivalent at one-fifth the cost
8. Manufacturer savings programs and their income limits
9. The plan-switching window: open enrollment strategy
10. When diabetes diagnosis changes everything
11. Medicare Advantage BCBSTX plans: the 2026 coverage gap
12. FAQ
13. Sources

The baseline answer: which BCBSTX plans cover Wegovy

BCBSTX operates as the largest health insurer in Texas, administering commercial plans, Medicare Advantage plans, and individual marketplace plans. Wegovy coverage varies by plan type:

Commercial employer plans: Coverage depends entirely on whether the employer purchased the obesity medication rider. This is an optional add-on that increases premiums by approximately $18 to $32 per member per month according to 2025 actuarial filings. Employers with 500+ employees purchase this rider about 24% of the time. Employers with under 100 employees purchase it about 9% of the time.

Individual marketplace plans (ACA exchange): Zero BCBSTX individual marketplace plans in Texas included obesity medication coverage in 2026 plan year. All plans contain explicit exclusion language: "Services and supplies for weight reduction or control, whether or not there is a diagnosis of obesity, including medications, are excluded."

Medicare Advantage plans administered by BCBSTX: Federal law prohibits Medicare coverage of weight-loss medications. The Treating and Reducing Obesity Act (TROA) has been introduced in Congress repeatedly since 2021 but has not passed as of April 2026. No Medicare Advantage plan, regardless of administrator, can cover Wegovy for obesity.

Medicaid plans administered by BCBSTX: Texas Medicaid does not cover Wegovy for obesity. Some states (California, Louisiana, North Carolina) added GLP-1 obesity coverage in 2024-2025. Texas has not.

The pattern: unless you have a large-employer commercial plan that specifically purchased the rider, assume you do not have coverage.

How to check your specific plan in under 3 minutes

The fastest verification path:

Step 1: Log into your BCBSTX member portal at bcbstx.com. Navigate to "Coverage and Benefits" or "Plan Documents."

Step 2: Download your Summary Plan Description (SPD) or Evidence of Coverage (EOC). Use the PDF search function (Ctrl+F or Cmd+F) and search for these exact terms in order:

• "obesity"
• "weight management"
• "GLP-1"
• "semaglutide"

Step 3: Look for one of three outcomes:

Outcome A (coverage exists): You find a section titled "Obesity Treatment" or "Weight Management Services" that lists covered medications. Wegovy will be listed by name or under "GLP-1 receptor agonists for obesity." This section will reference prior authorization requirements.

Outcome B (explicit exclusion): You find language like "Services for weight reduction or control are excluded" or "Medications for weight management are not covered." This is a hard no.

Outcome C (ambiguous or silent): The document doesn't mention obesity or weight management at all. This usually means exclusion by omission. Call the member services number on your card and ask specifically: "Does my plan cover Wegovy, NDC 0169-4517-13, for obesity without a diabetes diagnosis?"

The member services representative will check the formulary in real time. Get the representative's name and reference number for the call. If they say "yes," ask them to send written confirmation to your member portal.

The prior authorization process: requirements and timeline

If your plan includes obesity medication coverage, Wegovy still requires prior authorization. BCBSTX uses the following criteria as of 2026:

Medical criteria (all must be met):

• BMI 30 kg/m² or greater, OR BMI 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, cardiovascular disease)
• Age 18 or older (some plans extend to age 12+ with pediatric endocrinologist prescription)
• Documented physician-supervised weight loss attempt within the past 12 months, minimum 6 months duration, with recorded weights showing insufficient response (defined as less than 5% total body weight loss)
• No contraindications: no personal or family history of medullary thyroid carcinoma, no Multiple Endocrine Neoplasia syndrome type 2 (MEN2), not pregnant or planning pregnancy

Documentation requirements:

• ICD-10 diagnosis code E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified)
• Chart notes from the 6-month supervised weight loss attempt showing dates, weights, interventions (diet, exercise, behavioral counseling)
• Current weight and BMI measured within 30 days
• Comorbidity diagnoses if using the BMI 27+ pathway (must be documented with ICD-10 codes)

Submission process: Your prescribing provider submits the prior authorization through the BCBSTX provider portal or via fax to the pharmacy benefits manager (usually Prime Therapeutics for BCBSTX plans). The request includes the prescription, clinical documentation, and a letter of medical necessity.

Timeline:

• Standard prior authorization decision: 72 hours for urgent requests, 14 business days for standard requests
• Reality: average approval time is 18 business days based on 2024-2025 BCBSTX data
• If denied, first-level appeal adds another 14 to 21 business days
• Second-level appeal (external review) adds 30 to 45 days

Total time from submission to final answer if appealing a denial: 60 to 90 days. This is why many patients pursue alternatives rather than waiting through the appeals process.

Why most employer groups exclude the obesity rider

The obesity medication rider is expensive relative to utilization. Actuarial modeling from 2025 shows:

• Average annual cost per covered member for the obesity rider: $240 to $384 (premium increase)
• Average annual cost per user of obesity medications: $13,440 to $15,960 (Wegovy list price is $1,349.02 per month)
• Expected utilization rate: 1.8% to 2.4% of covered members will use obesity medications if offered

Employers run the math: for a 500-person group, adding the rider costs $120,000 to $192,000 in additional annual premiums. Expected utilization is 9 to 12 employees. The per-user subsidy is $10,000 to $16,000.

Compare that to the diabetes medication rider, which costs $60 to $90 per member per month but has 8% to 12% utilization. The per-user subsidy is much lower, and diabetes medications prevent costly downstream complications (dialysis, amputations, hospitalizations). The ROI is clearer.

Obesity medications are in an awkward middle ground in 2026. The clinical evidence for cardiovascular risk reduction is strong (SELECT trial showed 20% reduction in major adverse cardiac events for semaglutide), but the cost-benefit analysis for employers is harder to justify when employees can access compounded alternatives for under $300 per month.

The pattern we see: employers that offer the obesity rider tend to be in healthcare, technology, or professional services industries with higher average compensation and a benefits-differentiation strategy. Manufacturing, retail, and hospitality employers almost never purchase the rider.

What most coverage articles get wrong about "medical necessity"

The most common error in insurance coverage articles is conflating "medically necessary" with "covered." These are different concepts.

Medical necessity is a clinical determination. Wegovy is medically necessary for a patient with BMI 32, hypertension, and failed diet/exercise attempts. No physician would dispute that.

Coverage is a contractual determination. The plan document is a contract. If the contract excludes weight-loss medications, the medical necessity is irrelevant. The plan will deny the claim even if the medication is medically appropriate.

Most articles say something like: "If your doctor says you need Wegovy, insurance has to cover it." This is false. The plan document governs. If obesity medications are excluded, a letter of medical necessity from your physician will not override the exclusion.

The appeals process exists for coverage determinations, not plan exclusions. You can appeal if BCBSTX denies Wegovy because they claim you don't meet BMI criteria (a coverage determination). You cannot successfully appeal if the plan document explicitly excludes all obesity medications (a plan exclusion). The external review will uphold the denial because the plan is following its own contract.

This distinction matters because it changes your strategy. If you have a coverage determination denial, appeal. If you have a plan exclusion, appealing wastes 60 to 90 days. Move directly to the alternatives below.

How to tell the difference: Read the denial letter. If it says "not medically necessary" or "criteria not met," that's a coverage determination (appeal-worthy). If it says "excluded service" or "not a covered benefit," that's a plan exclusion (appeal will fail).

The four-path decision tree when BCBSTX says no

When BCBSTX does not cover Wegovy, you have four viable paths. The right path depends on your income, timeline, and risk tolerance.

Path 1: Compounded semaglutide (same active ingredient, lower cost)

Compounded semaglutide contains the same active pharmaceutical ingredient as Wegovy. It is prepared by a licensed compounding pharmacy in response to an individual prescription. Cost through FormBlends and similar platforms: $297 to $397 per month depending on dose.

Best for: Patients who want to start treatment immediately, have household income above 400% of federal poverty level (which disqualifies most assistance programs), and are comfortable with compounded medications.

Tradeoffs: Compounded semaglutide is not FDA-approved. It has not undergone the same manufacturing and stability testing as brand-name Wegovy. The FDA allows compounding when a drug is in shortage or when a prescriber determines a patient-specific need. As of April 2026, semaglutide remains on the FDA shortage list, making compounding legally permissible.

Timeline: 3 to 7 days from prescription to delivery.

Path 2: Novo Nordisk Wegovy Savings Card (for commercially insured patients)

Novo Nordisk offers a savings card that reduces out-of-pocket cost to $0 to $25 per month for patients with commercial insurance. The card does not work for government insurance (Medicare, Medicaid) or for patients paying cash.

Best for: Patients with BCBSTX commercial insurance where the plan covers Wegovy but has a high copay or coinsurance.

Tradeoffs: The card only works if your plan covers Wegovy. If Wegovy is excluded, the pharmacy will process the claim, the claim will deny, and the savings card cannot apply. This is the most misunderstood limitation. The savings card is a copay assistance program, not a coverage replacement program.

How to check eligibility: Go to wegovy.com/savings-and-coverage. Enter your insurance information. If the tool says "Your insurance plan does not cover Wegovy," the savings card will not help.

Path 3: Clinical trial enrollment

Multiple ongoing trials are studying semaglutide and tirzepatide for obesity, cardiovascular outcomes, and metabolic syndrome. Trial participants receive medication at no cost and close medical monitoring.

Best for: Patients who meet trial inclusion criteria (usually BMI 30+, age 18 to 75, no significant contraindications) and who value the monitoring and structured approach.

Tradeoffs: Trials have specific protocols. You may be randomized to placebo (though most obesity trials now use active comparator rather than placebo). You must attend regular study visits. You cannot choose your dose or titration schedule.

How to find trials: ClinicalTrials.gov, search "semaglutide obesity" or "tirzepatide obesity," filter by "Recruiting" status and location within 50 miles of your ZIP code. As of April 2026, 23 active trials in Texas are recruiting.

Timeline: Screening and enrollment take 2 to 6 weeks.

Path 4: Plan-year switching during open enrollment

If you have employer-sponsored insurance, you can switch to a plan with obesity coverage during the annual open enrollment period (typically November for January 1 effective date). If you have marketplace insurance, open enrollment runs November 1 to January 15 for most states.

Best for: Patients who can wait 6 to 10 months for coverage to begin and who have access to a plan option with the obesity rider.

Tradeoffs: You are locked into the new plan for 12 months. If the new plan has higher premiums or worse coverage for other services (higher deductible, narrower network), you are trading obesity coverage for other benefits.

How to evaluate: During open enrollment, request the Summary of Benefits and Coverage (SBC) for each plan option. Search the formulary for "semaglutide" and "Wegovy." Confirm the plan covers these for obesity (ICD-10 E66.x), not just diabetes (E11.x). Calculate total annual cost: (premium increase × 12) + (expected Wegovy copay × 12). Compare to $3,564 annual cost of compounded semaglutide ($297/month).

Timeline: 2 to 3 months from open enrollment to coverage effective date.

Compounded semaglutide: the clinical equivalent at one-fifth the cost

Compounded semaglutide is the same molecule as Wegovy. Both are semaglutide, a GLP-1 receptor agonist. The difference is manufacturing and regulatory pathway.

What compounding means: A licensed compounding pharmacy combines bulk semaglutide powder (sourced from FDA-registered suppliers) with bacteriostatic water and other excipients to create an injectable solution. The pharmacy prepares the medication in response to an individual prescription, not as a mass-produced product.

Legal status: Compounding is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when (1) a licensed prescriber writes a patient-specific prescription, and (2) the drug is in shortage or the prescriber identifies a patient-specific need. Semaglutide has been on the FDA shortage list since March 2022 and remains there as of April 2026.

Clinical equivalence: The active ingredient is identical. The pharmacokinetics (absorption, distribution, metabolism, excretion) are the same. The receptor binding is the same. The clinical effects on weight loss, glucose control, and cardiovascular risk are expected to be the same.

What is different:

• Stability testing: Brand-name Wegovy undergoes 24-month stability testing. Compounded semaglutide typically has 60 to 90-day beyond-use dating.
• Manufacturing oversight: Wegovy is manufactured under FDA Good Manufacturing Practices (GMP) with batch testing. Compounded medications are prepared under state pharmacy board oversight with less rigorous batch-to-batch testing.
• Delivery device: Wegovy comes in a prefilled single-dose pen. Compounded semaglutide comes in a multi-dose vial requiring manual injection with insulin syringes.

Cost comparison:

Product	Monthly cost (2.4 mg dose)	Annual cost
Wegovy (brand, no insurance)	$1,349.02	$16,188
Wegovy (with BCBSTX coverage, typical copay)	$50 to $150	$600 to $1,800
Compounded semaglutide (FormBlends)	$297	$3,564
Compounded semaglutide (other platforms)	$199 to $450	$2,388 to $5,400

The cost difference is the reason 68% of GLP-1 users in the U.S. were using compounded versions as of Q1 2026 according to IQVIA prescription data.

Safety considerations: Compounded semaglutide from a licensed U.S. pharmacy operating under state board oversight has a strong safety record. The FDA has issued warnings about compounded semaglutide from unlicensed or international sources, counterfeit products sold online, and products containing salt forms of semaglutide (semaglutide sodium, semaglutide acetate) rather than the base molecule. Stick with platforms that use PCAB-accredited or state-licensed compounding pharmacies.

Manufacturer savings programs and their income limits

Novo Nordisk's Wegovy Savings Card has specific eligibility rules that disqualify most patients who need it:

Who qualifies:

• Commercially insured patients whose plan covers Wegovy
• Household income below $100,000 for single-person households or below $200,000 for families (as of 2026 program terms)
• Not enrolled in Medicare, Medicaid, TRICARE, or any government insurance

Who does not qualify:

• Patients whose plan excludes Wegovy (the card cannot override a plan exclusion)
• Medicare and Medicaid patients (federal anti-kickback statute prohibits manufacturer copay assistance for government insurance)
• Patients paying cash (the card requires insurance adjudication first)
• Patients with household income above the program limits

The income limit problem: A household income of $200,000 sounds high, but in major Texas metros (Austin, Dallas, Houston), median household income for college-educated professionals is $140,000 to $180,000. A two-physician household or two-tech-worker household easily exceeds $200,000. These patients have commercial insurance, their plans often cover Wegovy, but they are disqualified from copay assistance by income.

The result: a patient with $220,000 household income and a 20% coinsurance plan pays $269.80 per month for Wegovy (20% of $1,349.02). Compounded semaglutide at $297 is nearly the same cost and does not require prior authorization or income verification.

Alternative manufacturer programs: Novo Nordisk also offers a patient assistance program (PAP) for uninsured or underinsured patients with household income below 400% of federal poverty level ($60,000 for single person, $124,800 for family of four in 2026). The PAP provides Wegovy at no cost but requires extensive income documentation (tax returns, pay stubs) and takes 4 to 8 weeks to process.

Comparison to compounded access: Compounded semaglutide has no income limits, no insurance requirements, and no waiting period beyond the 3 to 7 days for prescription and shipping. For patients above 400% FPL or with household income above the savings card limits, compounding is faster and often cheaper than navigating manufacturer programs.

The plan-switching window: open enrollment strategy

If you have flexibility to switch plans, the annual open enrollment period is your opportunity to gain obesity medication coverage. The strategy:

Step 1: Identify which plan options include the obesity rider (September to October, before open enrollment)

Request the Summary of Benefits and Coverage (SBC) and formulary for every plan your employer offers. Most employers offer 2 to 4 plan tiers (bronze, silver, gold, platinum or similar naming). Search each formulary for:

• Wegovy (semaglutide for obesity)
• Saxenda (liraglutide for obesity)
• Zepbound (tirzepatide for obesity, approved November 2023)

If any of these appear on the formulary with a tier assignment (Tier 3, Tier 4, specialty tier), the plan includes obesity coverage. If they are absent or listed as "not covered," the plan excludes obesity medications.

Step 2: Calculate total annual cost (October)

For each plan with obesity coverage, calculate:

• Annual premium difference vs your current plan
• Annual deductible
• Expected Wegovy copay or coinsurance per month
• Total: (premium increase × 12) + deductible + (Wegovy cost × 12)

Example:

• Current plan: $200/month premium, $1,500 deductible, Wegovy not covered
• Alternative plan: $285/month premium, $2,500 deductible, Wegovy covered at $75/month copay after deductible

Annual cost difference:

• Premium increase: ($285 - $200) × 12 = $1,020
• Deductible increase: $2,500 - $1,500 = $1,000
• Wegovy copay (assuming you hit deductible in Q1): $75 × 10 months = $750
• Total additional cost: $2,770

Compare to compounded semaglutide at $297/month = $3,564/year. The insurance route saves $794 annually in this example, but you are locked in for 12 months and must complete prior authorization.

Step 3: Enroll during the open enrollment window (November 1 to November 15 typically)

Submit your plan election. Coverage becomes effective January 1.

Step 4: Submit prior authorization in December

Do not wait until January. Submit the prior authorization in mid-December so it is approved by January 1. You will need:

• Prescription from your provider dated in December
• Documentation of 6-month weight loss attempt (this can be from the prior year)
• Current weight and BMI

If approved, your first fill ships in early January.

The risk: If the prior authorization is denied (criteria not met, documentation insufficient), you have switched to a more expensive plan for no benefit. You cannot switch back until the next open enrollment. This is why many patients start with compounded semaglutide rather than gambling on the plan-switching strategy.

When diabetes diagnosis changes everything

If you have type 2 diabetes (ICD-10 E11.x), the coverage landscape is completely different.

Ozempic (semaglutide for diabetes): Nearly all BCBSTX plans cover Ozempic for type 2 diabetes. It is a Tier 3 or specialty tier medication, typically requiring prior authorization but with much simpler criteria:

• Diagnosis of type 2 diabetes
• HbA1c 7.0% or higher, or documented inadequate control on metformin or other first-line agents

No 6-month weight loss attempt required. No BMI threshold. Approval rate is above 85% for first-submission prior authorizations.

The dosing loophole: Ozempic is FDA-approved at doses up to 2 mg per week for diabetes. Wegovy is dosed up to 2.4 mg per week for obesity. In practice, many prescribers dose Ozempic at 2 mg weekly for patients with diabetes and obesity, achieving near-equivalent weight loss to Wegovy.

Published data from the STEP 2 trial (semaglutide in patients with obesity and diabetes) showed 9.6% weight loss at 2.4 mg dose vs 7.0% weight loss at 1 mg dose (Wadden et al., Lancet 2021). The difference between 2 mg and 2.4 mg is marginal.

The diagnostic gray zone: Prediabetes (HbA1c 5.7% to 6.4%) does not qualify for Ozempic coverage. You need a diabetes diagnosis (HbA1c 6.5% or higher on two separate tests, or fasting glucose 126 mg/dL or higher on two separate tests).

Some patients with obesity and HbA1c in the 6.0% to 6.4% range are genuinely prediabetic and will progress to diabetes without intervention. GLP-1 medications prevent progression (SCALE trial showed 79% reduction in diabetes incidence over 3 years with liraglutide). But insurance will not cover until you cross the diagnostic threshold.

The ethical question: is it appropriate to delay treatment until prediabetes becomes diabetes to gain coverage? Most endocrinologists say no. The clinical approach is to treat prediabetes aggressively with lifestyle and medication to prevent diabetes, not wait for diabetes to develop. But the insurance incentive structure is backwards.

Pattern we see in FormBlends consultations: Patients with HbA1c 6.0% to 6.4%, BMI 32+, and strong family history of diabetes often pursue compounded semaglutide rather than waiting for diabetes diagnosis. The cost is lower than paying out-of-pocket for brand Wegovy, and treatment starts immediately rather than waiting for disease progression.

Medicare Advantage BCBSTX plans: the 2026 coverage gap

Federal law prohibits Medicare Part D from covering medications for weight loss. This is Section 1860D-2(e)(2)(A) of the Social Security Act, which excludes "agents when used for anorexia, weight loss, or weight gain."

What this means for Medicare Advantage: Even though BCBSTX administers Medicare Advantage plans in Texas, those plans cannot cover Wegovy for obesity. The prohibition is federal, not insurer-specific.

The diabetes exception: Medicare Advantage plans cover Ozempic (semaglutide) and Mounjaro (tirzepatide) for type 2 diabetes. If you have Medicare and a diabetes diagnosis, you have coverage. If you have Medicare and obesity without diabetes, you do not.

The TROA bill: The Treat and Reduce Obesity Act has been introduced in every Congress since 2012. It would eliminate the Part D exclusion for obesity medications. As of April 2026, the bill has 60 Senate cosponsors (needs 60 to overcome filibuster) and 210 House cosponsors (needs 218 to pass). It has not received a floor vote.

Advocacy groups (Obesity Action Coalition, The Obesity Society) estimate passage is likely in 2026 or 2027, but no timeline is certain. If TROA passes, Medicare Advantage plans would be required to cover FDA-approved obesity medications, and BCBSTX Medicare Advantage plans would cover Wegovy.

Current options for Medicare patients:

1. If you have diabetes, get Ozempic covered through Medicare Part D
2. If you do not have diabetes, pay out-of-pocket for Wegovy ($1,349/month) or use compounded semaglutide ($297/month)
3. Enroll in a clinical trial
4. Wait for TROA to pass (timeline uncertain)

The coverage gap affects 14.2 million Medicare beneficiaries with obesity as of 2025 CDC data. It is the largest unmet coverage need in the obesity medication space.

FAQ

Does BCBSTX cover Wegovy for weight loss? BCBSTX covers Wegovy only if your specific plan includes the optional obesity medication rider. Most BCBSTX plans exclude weight-loss medications. Check your Summary Plan Description or call member services to verify your plan's coverage.

How do I know if my BCBSTX plan covers obesity medications? Log into your BCBSTX member portal, download your plan documents, and search for "obesity" or "weight management." If you find a covered services section listing obesity medications, you have coverage. If you find exclusion language, you do not. When in doubt, call member services.

What is the prior authorization process for Wegovy with BCBSTX? Your provider submits clinical documentation showing BMI 30+ (or 27+ with comorbidity), a 6-month physician-supervised weight loss attempt with insufficient results, and no contraindications. Average approval time is 14 to 21 business days. Denials can be appealed.

Does the Wegovy savings card work if BCBSTX denies coverage? No. The Novo Nordisk savings card only reduces copays for patients whose insurance covers Wegovy. If your plan excludes obesity medications, the savings card cannot override the exclusion. The card is copay assistance, not coverage replacement.

Can I appeal if BCBSTX denies Wegovy? Yes, but success depends on the denial reason. If BCBSTX says you do not meet medical criteria (coverage determination), appeal with additional documentation. If BCBSTX says obesity medications are excluded from your plan (plan exclusion), appeals rarely succeed because the plan is following its contract.

What is compounded semaglutide and is it the same as Wegovy? Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide, a GLP-1 receptor agonist). It is prepared by a licensed compounding pharmacy in response to an individual prescription. It costs $297 to $397 per month vs $1,349 for brand Wegovy. It is not FDA-approved but is legal while semaglutide remains on the FDA shortage list.

Does BCBSTX Medicare Advantage cover Wegovy? No. Federal law prohibits Medicare Part D from covering weight-loss medications. BCBSTX Medicare Advantage plans cannot cover Wegovy for obesity. If you have type 2 diabetes, Medicare covers Ozempic (semaglutide for diabetes) at similar doses.

How much does Wegovy cost without insurance? Wegovy's list price is $1,349.02 per month ($16,188 annually). Pharmacy prices vary slightly but are typically within $50 of list price. No generic version exists as of April 2026. Novo Nordisk holds patent exclusivity until 2032.

Can I switch BCBSTX plans during open enrollment to get Wegovy coverage? Yes. During your employer's open enrollment period (typically November), you can switch to a plan that includes the obesity medication rider. Compare the annual cost of higher premiums plus Wegovy copays to the cost of compounded semaglutide before switching.

What BMI do I need for BCBSTX to cover Wegovy? BCBSTX requires BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease). BMI must be documented within 30 days of the prior authorization request.

Does BCBSTX cover Zepbound or Saxenda for weight loss? Coverage for Zepbound (tirzepatide) and Saxenda (liraglutide) follows the same pattern as Wegovy. If your plan includes the obesity medication rider, all three are typically covered. If obesity medications are excluded, none are covered. Check your specific formulary.

How long does BCBSTX prior authorization take for Wegovy? Standard timeline is 14 business days. Urgent requests are decided within 72 hours, but obesity medication requests rarely qualify as urgent. Average real-world approval time is 18 business days. If denied and appealed, add another 14 to 30 days per appeal level.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
3. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
5. Blue Cross Blue Shield of Texas. 2026 Summary of Benefits and Coverage. Published November 2025.
6. Blue Cross Blue Shield of Texas. Medical Policy: Obesity Treatment Medications. Policy updated January 2026.
7. Centers for Medicare and Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. Updated 2025.
8. FDA. Drug Shortages Database: Semaglutide Injection. Accessed April 2026.
9. IQVIA Institute. Use of GLP-1 Receptor Agonists in the U.S., 2021-2026. Published March 2026.
10. Novo Nordisk. Wegovy Prescribing Information. Revised December 2025.
11. American College of Gastroenterology. Clinical Guidelines: Diagnosis and Management of Obesity. 2022.
12. Congressional Budget Office. Cost Estimate: Treat and Reduce Obesity Act of 2025. Published February 2026.
13. National Institutes of Health. ClinicalTrials.gov: Semaglutide Obesity Trials. Accessed April 2026.
14. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: Obesity Prevalence 2023-2024. Published January 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Blue Cross Blue Shield of Texas (BCBSTX) is a trademark of Blue Cross Blue Shield Association. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.